Botanix Pharmaceuticals Ltd has released a press release.
Botanix announces new clinical program to target rosacea
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Botanix Pharmaceuticals
- Appendix 4E and Annual Report
- Botanix $40 Million US Lead Placement and Management Update
- Botanix Antimicrobial Platform Addresses Global Threat
- BTX 1801 Kills Superbugs Without Resistance World-First
- Study Confirms Anti-inflammatory and Other Properties of CBD
Later from Botanix Pharmaceuticals
- BOT Receives Grant for Synthetic Cannabidiol Analog Program
- Botanix Announces BTX 1503 Data and Progression to Phase 3
- Botanix Announces De-scheduling of Synthetic CBD
- Botanix Initiates BTX 1702 Rosacea Study
- Antimicrobial Platform Update and Launch of BTX 1801 Study
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals